Skip to main content

Table 1 Demographic characteristics of ICU-admitted patients treated with two different formulations of intravenous colistina

From: Comparison of colistin-induced nephrotoxicity between two different formulations of colistin in critically ill patients: a retrospective cohort study

  Overall patients Intravenous colistin P-value
Locolin® Colimycin®
No. of patients 195 95 100  
Age, years (SD) 73.8 (13.5) 75.2 (12.3) 72.4 (14.6) 0.142
Sex 0.069
Male 138 (70.8%) 73 (76.8%) 65 (65%)  
Female 57 (29.2%) 22 (23.2%) 35 (35%)  
BMI (SD) 22.3 (4.6) 21.7 (4.8) 22.8 (4.3) 0.106
Smoking 78 (40%) 40 (42.1%) 38 (38%) 0.559
Comorbidities  
Diabetes 57 (29.2%) 28 (29.5%) 29 (29%) 0.942
Malignancies 33 (16.9%) 24 (25.3%) 9 (9%) 0.002
Renal insufficiency (CCr < 30) 21 (10.8%) 10 (10.5%) 11 (11%) 0.915
Chronic liver diseases 16 (8.2%) 3 (3.2%) 13 (13%) 0.017
Heart failure 17 (8.7%) 8 (8.4%) 9 (9%) 0.886
CR-GNB culture sources  
Respiratory specimens 157 (80.5%) 75 (78.9%) 82 (82%) 0.591
Urine 11 (5.6%) 6 (6.3%) 5 (5%) 0.691
Blood 10 (5.1%) 4 (4.2%) 6 (6%) 0.571
Others 17 (8.7%) 10 (10.5%) 7 (7%) 0.383
CR-GNB species  
CRAB 141 (72.3%) 64 (67.4%) 77 (77%) 0.270
CRE 45 (23.1%) 28 (29.5%) 17 (17%) 0.051
CRPA 9 (4.6%) 3 (3.2%) 6 (6%) 0.344
Laboratory results (Mean, SD)  
Leukocytes (× 109 per L) 13.2 (9.0) 13.2 (8.3) 13.3 (9.7) 0.935
CRP (mg/dL) 10.0 (6.5) 10.3 (7.6) 9.6 (5.9) 0.464
Albumin level (median, IQR) 2.7 (2.4–3.0) 2.8 (2.5–3.1) 2.6 (2.3–2.9) 0.017
Concomitant nephrotoxins  
Aminoglycoside 22 (11.3%) 15 (15.8%) 7 (7%) 0.052
Vancomycin 20 (10.3%) 13 (13.7%) 7 (7%) 0.124
Intravenous contrast agent 39 (20.0%) 17 (17.9%) 22 (22%) 0.474
Disease severity  
APACHEII scores (median, IQR)b 24 (19–30) 25 (20–30) 24 (19–30) 0.768
Respiratory failured 175 (89.7%) 83 (87.4%) 92 (92%) 0.287
Septic shockd 61 (31.3%) 33 (34.7%) 28 (28%) 0.310
Intravenous colistin  
Daily dosage (MIU) (median, IQR) 8 (4–10) 8 (4–10) 8 (4–10) 0.814
Treatment duration (median, IQR) 7 (4–12) 7 (4–12) 7 (4–12) 0.782
Accumulated dosage (MIU) (median, IQR) 48 (28–80) 48 (28–64) 48 (24–88) 0.956
Inappropriate colistin dosage 23 (11.8%) 7 (7.4%) 16 (16%) 0.062
  1. APACHE II Acute Physiology and Chronic Health Evaluation II, BMI body mass index, ICU intensive care unit, IQR interquartile range, CCr creatinine clearance, CR-GNB carbapenem-resistant gram-negative bacteria, SD standard deviation
  2. aData are presented as n (%)
  3. bIncluding abscess, ascites, CSF, and pericardial effusion
  4. cEvaluated on the day of ICU admission
  5. dPresent on the day of sample collection
Back to article page

Antimicrobial Resistance & Infection Control

ISSN: 2047-2994

Contact us